China Biologic Products Inc. (NASDAQ:CBPO)

Friday, February 24, 2017 | Web News
Fourth Quarter 2016 Financial Results Total sales in the fourth quarter of 2016 increased by 21.7% in RMB terms, or increased by 13.6%...
Thursday, November 3, 2016 | Web News
Third Quarter 2016 Financial Results Total Sales Up 9.8% YoY to $86.5 Million and Net Income Up 24.0% YoY to...
Wednesday, October 26, 2016 | Web News
BEIJING, October 26, 2016 /PRNewswire/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "...

At least one FIE exists in the corporate structure

China Biologic Products, Inc., through its indirect majority-owned subsidiary, Shandong Taibang, is currently the only plasma-based biopharmaceutical company approved by the government of Shandong Province, the second largest province with a population of 93 million. The company is engaged primarily in research, manufacturing, and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China.

Web site:

Last updated March 17, 2008